Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2015 12:32 ET | Source: BELIMO Holding AG

BELIMO Holding AG: Elections of the Board of Directors

RetirementCompany co-founder Walter Linsi will be retiring from the Board of Directors for age reasons at the Annual General Meeting of April 20, 2015. New election for the term of office of one...
March 23, 2015 12:32 ET | Source: BELIMO Holding AG

BELIMO Holding AG: Wahlen in den Verwaltungsrat

RücktrittAuf die ordentliche Generalversammlung vom 20. April 2015 scheidet der Firmenmitgründer Walter Linsi aus Altersgründen aus dem Verwaltungsrat aus. Neuwahl für die Amtsdauer von einem...
March 23, 2015 06:13 ET | Source: Sika AG

Sika AG: COURT OF ZUG DENIES ALL REQUESTS OF SCHENKER-WINKLER HOLDING

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} In the proceedings regarding the...
March 23, 2015 06:13 ET | Source: Sika AG

Sika AG: KANTONSGERICHT ZUG WEIST SÄMTLICHE ANTRÄGE VON SCHENKER-WINKLER HOLDING AB

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Im Verfahren bezüglich der...
March 23, 2015 02:00 ET | Source: BELIMO Holding AG

BELIMO Holding AG: Again solid growth and increased net income

The Belimo Group had a successful 2014. Sales rose in Swiss francs by 4.5 percent to CHF 493.9 million. Adjusted for currencies, the growth rate was 6.6 percent. In the second half-year, the...
March 23, 2015 02:00 ET | Source: BELIMO Holding AG

BELIMO Holding AG: Erneut solides Wachstum und Gewinnsteigerung

Die Belimo-Gruppe blickt auf ein erfolgreiches 2014 zurück. Der Umsatz stieg in Schweizer Franken um 4.5 Prozent auf CHF 493.9 Millionen. Währungsbereinigt entspricht dies einem Wachstum von 6.6...
March 21, 2015 07:00 ET | Source: Novartis Pharma AG

Novartis' Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in psoriasis patients

After two full years of therapy with Cosentyx 300 mg, almost 9 out of 10 psoriasis patients sustained their PASI 75 response[1] New data at AAD shows 7 out of 10 psoriasis patients, who were...
March 20, 2015 12:30 ET | Source: Novartis Pharma AG

New Novartis data shows Cosentyx(TM) is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of psoriasis patients

CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx(TM) compared to Stelara® at Week 16[1] Cosentyx showed greater improvements...
March 19, 2015 16:30 ET | Source: GAM Holding AG

Änderung im Verwaltungsrat der GAM Holding AG per ordentlicher Generalversammlung 2015

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Zürich, 19. März 2015 Dieter Enkelmann teilte...
March 19, 2015 16:30 ET | Source: GAM Holding AG

Change in the Board of Directors of GAM Holding AG as of the 2015 Annual General Meeting

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Zurich, 19 March 2015 Dieter Enkelmann today...